A cumulative dose safety and tolerability crossover study of arformoterol tartrate inhalation solution and levalbuterol hydrochloride [levosalbutamol] inhalation solution in pediatric subjects (aged 2 to 11 years of age) with asthma.
Latest Information Update: 11 Aug 2023
Price :
$35 *
At a glance
- Drugs Arformoterol (Primary) ; Levosalbutamol
- Indications Asthma
- Focus Adverse reactions
- Sponsors Sumitomo Pharma America
- 01 Aug 2011 Results published in Pediatric Pulmonology.
- 12 Feb 2010 Actual patient number (53) added as reported by ClinicalTrials.gov.
- 02 Dec 2008 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.